61352 Federal Register / Vol. 65, No. 201 / Tuesday, October 17, 2000 / Notices

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended

Notice of Meeting

Notice is hereby given of a change in

the meeting of the Center for Scientific

Review Special Emphasis Panel,

September 26, 2000, 12:30 p.m. to

September 26, 2000 2:30 p.m., NIH,

Rockledge 2, Bethesda, MD 20892

which was published in the Federal

Register on September 21, 2000, 65 FR

57201–57202.

The meeting will be held October 24,

2000, from 11 a.m. to 12:30 p.m. The

location remains the same. The meeting

is closed to the public.

Dated: October 6, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–26577 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended

Notice of Meeting

Notice is hereby given of a change in

the meeting of the Diagnostic Radiology

Study Section, October 16, 2000, 8 am

to October 17, 2000, 5 pm, Georgetown

Holiday Inn, 2101 Wisconsin Avenue,

NW, Washington, DC 20007 which was

published in the Federal Register on

October 5, 2000, 65 FR 59454–59456.

The meeting will be held at the

Georgetown Suites, 1111 30th Street,

NW, Washington, DC. The dates and

time remain the same. The meeting is

closed to the public.

Dated: October 6, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–26578 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Prospective Grant of Exclusive

License: Insulin Producing Cells

Differentiated from Non-Insulin

Producing Cells by GLP–1 and

Exendin–4 and Use Thereof

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: PCT Patent

Application Serial Number PCT/US99/

180899 (PHS Ref. E–151–97/1) entitled

‘‘Insulin Producing Cells Differentiated

from Non-Insulin Producing Cells by

GLP–1 and Exendin–4 and Use Thereof’’

filed on August 18, 1999, claiming

priority of August 10, 1998, to Amylin

Pharmaceuticals, Inc., having a place of

business in San Diego, CA. The patent

rights in this invention have been

assigned to the United States America.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before

December 18, 2000 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: John Rambosek, Ph.D.,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Email: jr312d@nih.gov;

Telephone: (301) 496–7056, ext. 270;

Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION: The patent

application relates to a population of

insulin producing cells differentiated

from non-insulin producing cells by

contacting the non-insulin producing

cells with Glucagon-like peptide–1

(GLP–1), Exendin–4, or related peptides.

The application also relates to the

methods for obtaining the insulin

producing cells and therapeutic uses in

the treatment of diabetes mellitus.

The prospective exclusive license will

be royalty bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be limited to the

field of use for development of products

and methods for treatment of diabetes.

The field for use would include

development, use, manufacture,

distribution, import, export, marketing

and sale of the licensed invention,

throughout the world. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: October 5, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–26582 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Public Health Service

National Toxicology Program; National

Toxicology Program (NTP) Board of

Scientific Counselors’ Meeting; Review

of Nominations for Listing in the 10th

Report on Carcinogens

Pursuant to Public Law 92–463,

notice is hereby given of the next

meeting of the NTP Board of Scientific

Counselors’ Report on Carcinogens

(RoC) Subcommittee to be held on

December 13, 14, and 15, 2000, at the

Wyndham City Center, 1143 New

Hampshire Ave., Washington, DC

20037. On December 13, registration

will begin at 9 a.m. and the meeting will

begin at 9:30 a.m. On December 14 and

15, the meeting will begin at 8:30 a.m.

Pre-registration is not required;

however, persons requesting time to

make oral, public comments are asked

to notify Dr. Mary S. Wolfe, Executive

Secretary, prior to the meeting (contact

information given below). The agenda

covers the peer review of agents,

substances, mixtures, or exposure

circumstances nominated for listing in

the 10th Report on Carcinogens, and

includes an opportunity for public

input.

Background

The Department of Health and Human

Services (DHHS) Report on Carcinogens